Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | NRAS |
Variant | A59X |
Impact List | missense |
Protein Effect | unknown |
Gene Variant Descriptions | NRAS A59X indicates any NRAS missense mutation that results in the replacement of the alanine (A) at amino acid 59 by a different amino acid. |
Associated Drug Resistance | |
Category Variants Paths |
NRAS mutant NRAS exon3 NRAS A59X |
Transcript | NM_002524.5 |
gDNA | chr1:g.114713913_114713915 |
cDNA | c.175_177 |
Protein | p.A59 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_002524 | chr1:g.114713913_114713915 | c.175_177 | p.A59 | RefSeq | GRCh38/hg38 |
NM_002524.4 | chr1:g.114713913_114713915 | c.175_177 | p.A59 | RefSeq | GRCh38/hg38 |
NM_002524.5 | chr1:g.114713913_114713915 | c.175_177 | p.A59 | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
NRAS A59X | colorectal cancer | resistant | Cetuximab | FDA contraindicated | Actionable | Erbitux (cetuximab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov). | detail... |
NRAS A59X | colorectal cancer | resistant | Panitumumab | FDA contraindicated | Actionable | Vectibix (panitumumab) treatment of colorectal cancer patients with NRAS exon 3, codon 59 mutations is contraindicated (FDA.gov). | detail... |